**Question:** True about gastrinoma are all except

A. Gastrinomas are a type of neuroendocrine tumor that secretes gastrin, a hormone involved in gastric acid secretion.
B. Gastrinomas are exclusively found in the pancreas.
C. Gastrinomas are primarily associated with Zollinger-Ellison syndrome, a rare disorder characterized by excessive gastric acid secretion.
D. Gastrinomas are sensitive to treatment with somatostatin analogs.

**Correct Answer:**

B. **Gastrinomas are exclusively found in the pancreas.**

Gastrinomas, also known as Zollinger-Ellison syndrome tumors, are a type of neuroendocrine tumor originating from the enterochromaffin-like (ECL) cells in the stomach. Although they can secrete gastrin, they are not exclusively located in the pancreas. Gastrinomas can arise from ECL cells in the stomach, and the primary site of origin is crucial for understanding their clinical presentation, management, and prognosis.

**Why the Correct Answer is Right:**

Gastrinomas are a subset of neuroendocrine tumors, which are characterized by the production of hormones or other signaling molecules by cells within the endocrine system. In the case of gastrinomas, the hormone being produced is gastrin, which stimulates gastric acid secretion and promotes gastric acid production. However, the correct statement is that they are not exclusively located in the pancreas, as they can arise from ECL cells in the stomach as well.

**Why Each Wrong Option is Incorrect:**

A. **Gastrinomas are a type of neuroendocrine tumor.** This option is correct as it highlights the fundamental nature of gastrinomas. However, it does not address the specific site of origin.

C. **Gastrinomas are primarily associated with Zollinger-Ellison syndrome.** While gastrinomas are indeed part of Zollinger-Ellison syndrome, the statement "exclusively found in the pancreas" is incorrect.

D. **Gastrinomas are sensitive to treatment with somatostatin analogs.** Somatostatin analogs can be effective in controlling symptoms and reducing gastrin secretion in patients with Zollinger-Ellison syndrome, but they are not necessarily limited to the pancreas, as mentioned in option B.

**Clinical Pearls:**

Understanding the primary site of gastrinoma origin is crucial in managing patients with Zollinger-Ellison syndrome. The primary focus is on the stomach, as the tumors are derived from ECL cells, while the pancreas is secondary to the hormonal imbalance caused by the tumor. Treatment options, such as somatostatin analogs, can be effective in controlling symptoms but are not limited to the pancreas.